When it comes to large cap and a Pharma Major, one should not lose sight on the fundamentals of Dr Reddy Lab.With market cap of around 53000, it is currently under priced ; this stock becomes more attractive since its expecting a green signal from USFDA for its product.
Having undergone a quantum jump in reserves for Mar 2015 when compared with figures for Mar 2014 from 9243 crore to 10548 (though sales and net profit was down), it is enjoying a hefty book value of 623 with decent dividend pay out of 400% on the FV of Rs.5-/ A virtually debt free company with respectable price to earning when compared with industry peers, its current EPS (on TTM basis) ast 113 is very very interesting.
The stock is currently under priced. The fair value of DRL is around 3500 sooner than later.
Kindly see that buying is resorted in moderate numbers.
Invest n Enjoy